Ord Minnett sets AUD 25.00 target for EBOS Group stock

Published on 10/27/2026 at 19:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

FY2026 revenue reached AUD 13.49 billion, up 9.90 percent. EBOS Group stock costs EUR 10.40 on October 27, 2026 at 7:07 p.m. CEST.

Analyst target and earnings

Ord Minnett set an AUD 25.00 price target for EBOS Group on October 21, 2026.
Fiscal year 2026 revenue reached AUD 13.49 billion, up 9.90 percent.
EBOS Group stock costs EUR 10.40 at Lang & Schwarz on October 27, 2026 at 7:07 p.m. CEST.

EBO, NZEBOE0001S6, Illustration mit AI erstellt.

EBOS Group (ISIN NZEBOE0001S6) received a fresh AUD 25.00 price target from Ord Minnett on October 21, 2026. The Australian healthcare distributor also posted fiscal year 2026 revenue of AUD 13.49 billion, up 9.90 percent, while underlying EBITDA rose 5.00 percent to AUD 614.00 million, according to Quartr. EBOS Group was trading at EUR 10.40 at Lang & Schwarz on October 27, 2026 at 7:07 p.m. CEST.

AUD 25.00 target leaves room

Ord Minnett analyst Tom Godfrey maintained a Buy rating and set the AUD 25.00 target, as Markets Insider reported on October 22, 2026. The same report said Morgans maintained a Buy rating with an AUD 22.93 target. Against the AUD 16.54 quote for the Australian listing on October 27, 2026, the Ord Minnett target stood 51.15 percent above the price.

What do the results imply?

The fiscal year 2026 figures show growth with a narrower earnings conversion. Underlying NPAT was AUD 250.00 million, down 3.10 percent, while underlying EPS fell 7.30 percent to 121.70 cents. The company said all eight new facilities were operational by June 30, 2026, completing its major investment cycle.

Capital spending is turning lower

EBOS spent AUD 145.00 million on capital expenditure in fiscal year 2026. For fiscal year 2027, the company reaffirmed underlying EBITDA guidance of AUD 635.00 million to AUD 655.00 million and indicated capital expenditure of AUD 100.00 million. Net leverage ended fiscal year 2026 at 2.10 times, within the stated 1.70 to 2.30 times target range.

Stock price remains the market frame

EBOS operates in healthcare and animal care distribution across Australia and New Zealand. Its business includes pharmaceutical wholesale, medical products, pharmacy services and animal care brands. The latest analyst targets therefore place the emphasis on whether lower capital spending can translate into stronger earnings growth after the investment cycle.

EUR 10.40 after Xetra hours

The euro quote was EUR 10.40 at Lang & Schwarz on October 27, 2026 at 7:07 p.m. CEST, during after-hours trading. The further course of trading is shown by the continuously updated real-time quote of EBOS Group stock.